Enliven Therapeutics
ELVNELVN · Stock Price
Historical price data
Overview
Enliven Therapeutics is a clinical-stage biotech focused on developing precision small molecule kinase inhibitors to help cancer patients live longer and better lives. The company leverages a deep expertise in kinase biology and medicinal chemistry to create highly selective, combinable drugs that overcome resistance and address unmet needs. With a lead asset, ELVN-001, showing positive initial Phase 1b data in CML and a robust pipeline, Enliven is strategically positioned to advance novel therapies in competitive oncology markets.
Technology Platform
A rational design platform for next-generation small molecule kinase inhibitors, focusing on enhanced selectivity, combinability, resistance management, CNS penetration, and improved safety profiles.
Pipeline
4| Drug | Indication | Stage | Watch |
|---|---|---|---|
| ELVN-001 | Chronic Myeloid Leukemia | Phase 1 | |
| ELVN-002 + Fam-Trastuzumab Deruxtecan-Nxki + Trastuzumab emt... | HER2 Mutant Non-small Cell Lung Cancer | Phase 1 | |
| ELVN-002 + Trastuzumab + 5-Fluorouracil + Oxaliplatin + Cape... | HER2-positive Breast Cancer | Phase 1 | |
| ELVN-001 | CML (Chronic Myelogenous Leukemia) | Phase 1 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Enliven faces intense competition from large pharma and biotech companies with approved and pipeline kinase inhibitors. Its differentiation relies on superior drug design (selectivity, CNS penetration) and a team with a proven track record of discovering successful drugs in this class.